The injection is the first treatment for ulcerative colitis that targets p19, a specific protein subunit that contributes to ulcerative colitis-related inflammation, according to an Oct. 26 news release from the drugmaker.
Omvoh will be available in the United States in the coming weeks. The drug was approved in Japan and the European Union earlier this year, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.